Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Demonstration of Advanced Data Mining Tools for Optimization of Pellets Employing Modified Extrusion-pelletization Technique

Author(s): Hardika Rana*, Mansi Dholakia, Mukesh Gohel, Abdelwahab Omri, Vaishali Thakkar and Tejal Gandhi

Volume 16, Issue 2, 2021

Published on: 17 December, 2020

Page: [154 - 169] Pages: 16

DOI: 10.2174/1574885515999201217155123

Price: $65

Abstract

Background: The multi particulate drug delivery system is preferred due to its numerous advantages but the batch to batch consistency and to achieve desired physical properties are the major challenges in the formulation of such dosage form.

Objective: The objective of the present study was to explore the concept of quality by design for the development of galantamine HBr controlled release pellets using a modified palletization technique.

Methods: Compritol 888 and Ethocel were chosen as hydrophobic release retardants, while Avicel was chosen as pelletization aid. A compatibility study was conducted between the drug and excipients. Drug loaded extrudes were prepared by using a mixture of isopropyl alcohol, and dichloromethane. Before converting the wet extrudes into pellets, pregelatinized starch was sprinkled on them to improve the physical properties of the pellets. The pellets were characterized for size, shape, and flow. The critical evaluation parameter was the drug dissolution pattern in distilled water. The dissolution data were treated with advanced data mining techniques. The in-vivo profile was predicted employing pharmacokinetic parameters of the drug and in-vitro drug release data of optimized batch pellets.

Results: The failure mode and effect analysis revealed that the amount of Compritol 888 ATO and Ethocel were the most critical formulation parameters. The results of FTIR and DSC revealed compatibility between the drug and the excipients. The spherical pellets exhibited good flow. The drug dissolution studies of the batches, prepared according to the central composite design, revealed modified drug release. Multiple regression analysis and analysis of variance were performed to identify statistically significant factors. Contour plots demonstrated the impact of the amount of Compritol 888 and ethyl cellulose. The Design-Expert software was used to identify optimized formulation. The predicted in-vivo plasma concentration-time profile revealed the modified drug release up to 12h.

Conclusion: Compritol and Ethocel were able to retard the drug release up to 12 hrs in distilled water. The innovative finding of this study is the use of a dry binder (pregelatinized starch) to improve the characteristics of pellets. Other dry binders are expected to show a similar effect. The newer processing technique can be of use in the industry.

Keywords: Galantamine HBr, QbD, modified extrusion spheronization method, compritol, pregelatinized starch, physical properties of the pellets.

« Previous Next »
Graphical Abstract

[1]
Shah N, Mehta T, Gohel M. Formulation and Optimization of Multiparticulate Drug Delivery System Approach for High Drug Loading AAPS PharmSciTech 2016.
[2]
Gandhi R, Kaul CL, Panchagnula R. Extrusion and spheronization in the development of oral controlled-release PSST 1999. ; 2(4)
[3]
Akhgari A, Abbaspour MR, Pirmoradi S. Preparation and evaluation of pellets using acacia and tragacanth by extrusion-spheronization. Daru 2011; 19(6): 417-23.
[PMID: 23008687]
[4]
Muley S, Nandgude T, Poddar S. Extrusion – spheronization a promising pelletization technique : In-depth review. Asian J Pharm Sci [Internet] 2016; 11(6): 684-99.
[http://dx.doi.org/10.1016/j.ajps.2016.08.001]
[5]
Lavanya K. Pelletization Technology: A quick review. Int J Pharm Sci Res 2011; 2(6): 1337-55.
[6]
Wang J, Kan S, Chen T, Liu J. Application of quality by design (QbD) to formulation and processing of naproxen pellets by extrusion-spheronization. Pharm Dev Technol 2015; 20(2): 246-56.
[http://dx.doi.org/10.3109/10837450.2014.908300] [PMID: 25069591]
[7]
Khanahmadi M, Farhud DD, Malmir M. Genetic of Alzheimer’s disease: A narrative review article. Iran J Public Health 2015; 44(7): 892-901.
[PMID: 26576367]
[8]
Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s diseaseThe Lancet. Elsevier Ltd 2016; pp. 1-13.
[9]
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement 2017; 2017: 1-50.
[http://dx.doi.org/10.1016/j.jalz.2017.02.001]
[10]
Theleritis C, Siarkos K, Katirtzoglou E, Politis A. Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease: A systematic review across modalities. J Geriatr Psychiatry Neurol 2017; 30(1): 26-49.
[http://dx.doi.org/10.1177/0891988716678684] [PMID: 28248559]
[11]
Kuna Y, Kumari N. Chronic effects of anti-Alzheimer ’ s drug, Galantamine hydrobromide on cholinergic system of mice brain. J Pharm Res 2013; 6(7): 714-9.
[http://dx.doi.org/10.1016/j.jopr.2013.06.010]
[12]
Yang S. Preparation and evaluation of novel galantamine hydrobromide sustained-release capsule. Bangladesh J Pharmacol 2016; 2017(11): 1-10.
[http://dx.doi.org/10.3329/bjp.v11iS1.26417]
[13]
Yan HX, Zhang SS, He JH, Liu JP. Application of ethyl cellulose, microcrystalline cellulose and octadecanol for wax based floating solid dispersion pellets. Carbohydr Polym 2016; 148(1): 143-52.
[http://dx.doi.org/10.1016/j.carbpol.2016.04.050] [PMID: 27185125]
[14]
Ali MT, Fule R, Sav A, Amin P. Porous starch: a novel carrier for solubility enhancement of carbamazepine. AAPS PharmSciTech 2013; 14(3): 919-26.
[http://dx.doi.org/10.1208/s12249-013-9985-6] [PMID: 23715951]
[15]
Patel N, Thakkar V, Moradiya P, Gandhi T, Gohel M. Optimization of curcumin loaded vaginal in-situ hydrogel by box- behnken statistical design for contraception. J Drug Deliv Sci Technol 2015; 29(1): 55-68.
[http://dx.doi.org/10.1016/j.jddst.2015.06.002]
[16]
Ibrahim MA, El-Badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J 2014; 22(2): 149-56.
[http://dx.doi.org/10.1016/j.jsps.2013.01.011] [PMID: 24648827]
[17]
Gregg Claycamp H. Perspective on Quality Risk Management of Pharmaceutical Quality. Drug Inf J 2007; 41(3): 353-67.
[http://dx.doi.org/10.1177/009286150704100309]
[18]
Dave VS, Fahmy RM, Bensley D, Hoag SW. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets. Drug Dev Ind Pharm 2012; 38(10): 1240-53.
[http://dx.doi.org/10.3109/03639045.2011.645831] [PMID: 22257339]
[19]
Dave VS, Fahmy RM, Hoag SW. Investigation of the physical-mechanical properties of Eudragit(®) RS PO/RL PO and their mixtures with common pharmaceutical excipients. Drug Dev Ind Pharm 2013; 39(7): 1113-25.
[http://dx.doi.org/10.3109/03639045.2012.714786] [PMID: 22994144]
[20]
MIDDLE J.. A review of: “ Introduction to Quality Control. ” By KAORU ISHIKAWA. Int J Prod Res 1992; 30(12): 2952-.http://www.tandfonline.com/doi/abs/10.1080/00207549208948202
[http://dx.doi.org/10.1080/00207549208948202]
[21]
Stamatis DH. Failure Mode And Effect Analysis FMEA from Theory to Execution. 2nd ed. Milwaukee: ASQ Quality Press 2003; pp. 1-459.
[22]
Mahdizadeh M, Zamanzade E. A new reliability measure in ranked set sampling. Stat Hefte 2018; 59(3): 861-91.
[23]
Zamanzade E, Mahdizadeh M. Using ranked set sampling with extreme ranks in estimating the population proportion. Stat Methods Med Res 2020; 29(1): 165-77.
[http://dx.doi.org/10.1177/0962280218823793] [PMID: 30706764]
[24]
Fahmy R, Kona R, Dandu R, Xie W, Claycamp G, Hoag SW. Quality by design I: Application of failure mode effect analysis (FMEA) and Plackett-Burman design of experiments in the identification of “main factors” in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride immediate-release tablets. AAPS PharmSciTech 2012; 13(4): 1243-54.
[http://dx.doi.org/10.1208/s12249-012-9844-x] [PMID: 22993122]
[25]
Gurram RK, Gandra S, Shastri NR. Design and optimization of disintegrating pellets of MCC by non-aqueous extrusion process using statistical tools. Eur J Pharm Sci 2016; 84(1): 146-56.
[http://dx.doi.org/10.1016/j.ejps.2016.01.021] [PMID: 26812204]
[26]
Mahdizadeh M, Zamanzade E. New goodness of fit tests for the Cauchy distribution. J Appl Stat 2017; 44(6): 1106-21.
[http://dx.doi.org/10.1080/02664763.2016.1193726]
[27]
Singh S, Baghel RS, Yadav L. A review on solid dispersion Int J Pharm life Sci 2011 ; 2(9): 1078-95..
[28]
Derringer GC, Suich R. Simultaneous Optimization of Several Response Variables. J Qual Technol 1980; 12(4): 214-9.
[http://dx.doi.org/10.1080/00224065.1980.11980968]
[29]
Kleinebudde P. Application of low substituted hydroxypropylcellulose (L-HPC) in the production of pellets using extrusion/spheronization. Int J Pharm 1993; 96(1–3): 119-28.
[http://dx.doi.org/10.1016/0378-5173(93)90219-6]
[30]
Michie H, Podczeck F, Newton JM. The influence of plate design on the properties of pellets produced by extrusion and spheronization. Int J Pharm 2012; 434(1-2): 175-82.
[http://dx.doi.org/10.1016/j.ijpharm.2012.05.050] [PMID: 22659150]
[31]
Goyanes A, Martínez-Pacheco R. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization. Drug Dev Ind Pharm 2015; 41(3): 362-8.
[http://dx.doi.org/10.3109/03639045.2013.861479] [PMID: 24279425]
[32]
Podczeck F, Newton JM. Influence of the standing time of the extrudate and speed of rotation of the spheroniser plate on the properties of pellets produced by extrusion and spheronization. Adv Powder Technol 2013; 25(2): 1-7.
[http://dx.doi.org/10.1016/j.apt.2013.10.011]
[33]
El-mahdi IM, El-shhibia SA. Effect of spheronizer plate design on the spheronization of ketoprofen. Futur J Pharm Sci [Internet] 2017; 3(2): 153-7.
[http://dx.doi.org/10.1016/j.fjps.2017.05.004]
[34]
Gangurde AB, Sav AK, Javeer SD, Moravkar KK, Pawar JN, Amin PD. Modified extrusion-spheronization as a technique of microencapsulation for stabilization of choline bitartrate using hydrogenated soya bean oil. Int J Pharm Investig 2015; 5(4): 275-83.
[http://dx.doi.org/10.4103/2230-973X.167696] [PMID: 26682198]
[35]
Kunal P, Gohel MC, Parikh RK, Bariya S. Sustained Release Floating Microspheres Of Acyclovir: Formulation, Optimization, Characterization And In Vitro Evaluation. IJDDR 2011; 3(1): 242-51.
[36]
Goyanes A, Souto C, Martínez-Pacheco R. A comparison of chitosan-silica and sodium starch glycolate as disintegrants for spheronized extruded microcrystalline cellulose pellets. Drug Dev Ind Pharm 2011; 37(7): 825-31.
[http://dx.doi.org/10.3109/03639045.2010.545415] [PMID: 21405942]
[37]
Mallipeddi R, Saripella KK, Neau SH. Use of fine particle ethylcellulose as the diluent in the production of pellets by extrusion-spheronization. Saudi Pharm J 2014; 22(4): 360-72.
[http://dx.doi.org/10.1016/j.jsps.2013.11.001] [PMID: 25161381]
[38]
USP Revision Bulletin. Galantamine Extended-Release Capsules. USP Revision Bulletin Official 2016; pp. 1-5.
[39]
USP. The Galantamine Tablets official monograph USP Revision Bulletin official 2016.https://www.uspnf.com/sites/default/files/usp_pdf/EN/USPNF/revisions/galantamine_tablets.pdf
[40]
Varelas CG, Dixon DG, Steiner CA. Zero-order release from biphasic polymer hydrogels. J Control Release 1995; 34(3): 185-92.
[http://dx.doi.org/10.1016/0168-3659(94)00085-9]
[41]
Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci 1967; 56(10): 1238-42.
[http://dx.doi.org/10.1002/jps.2600561005] [PMID: 6059440]
[42]
Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci 1969; 58(10): 1253-7.
[http://dx.doi.org/10.1002/jps.2600581021] [PMID: 5349114]
[43]
Korsmayer RW, Gumy R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers Int jouranl Pharm 1983. ; 15(1): 25-35.
[http://dx.doi.org/10.1016/0378-5173(83)90064-9]
[44]
Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2012; 64: 163-74.http://www.sciencedirect.com/science/article/pii/S0169409X12002888
[45]
Janseen Pharmaceuticals. NDA Lable: Razadyne ER, Galantamine HBr extended-release capsules . 2011.https://www.accessdata. fda.gov/drugsatfda_docs/label/2004/021615lbl.pdf
[46]
Singhvi G, Shah A, Yadav N, Saha RN. Prediction of in vivo plasma concentration – time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method. Drug Dev Ind Pharm 2013; 41(1): 1-4.
[47]
Gohel DrMukesh, Delvadia R R, Parikh D C, et al. . Simplified Mathematical Approach for Back Calculation in Wagner-Nelson Method. Pharm Rev 2005; 3(2)
[48]
Cheng C, Wu P, Lee H, Hsu K. Development and validation of an in vitro e in vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations. Yao Wu Shi Pin Fen Xi 2013; 22(2): 257-63..
[http://dx.doi.org/10.1016/j.jfda.2013.09.016]

Rights & Permissions Print Cite
Article Metrics
14
1
© 2024 Bentham Science Publishers | Privacy Policy